University of Groningen

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

Bolhuis, Mathieu S; van der Werf, Tjip S; Akkerman, Onno W

Published in:
New England Journal of Medicine

DOI:
[10.1056/NEJMc2009939](https://doi.org/10.1056/NEJMc2009939)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Bolhuis, M. S., van der Werf, T. S., & Akkerman, O. W. (2020). Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. *New England Journal of Medicine*, 382(24), 2376-2377.
<https://doi.org/10.1056/NEJMc2009939>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

TO THE EDITOR: Conradie et al. (March 5 issue)¹ report that in the Nix-TB study, 90% of the patients with drug-resistant tuberculosis had treatment success, although 5.3% of the patients with positive baseline tuberculosis cultures (3 of 57 patients) had bedaquiline resistance, with minimum inhibitory concentrations (MICs) above the critical concentration. In the PRAXIS study involving patients with drug-resistant tuberculosis who were treated with bedaquiline, we found that 5.4% of the patients with positive baseline cultures (5 of 92 patients) had mutations in the bedaquiline resistance gene *Rv0678*, with MICs near the critical concentration.² Three of the 5 patients had an unsuccessful outcome. MICs near the critical concentration for other tuberculosis drugs have been associated with treatment failure.³ The authors of the Nix-TB study do not state whether patients with baseline bedaquiline resistance had worse outcomes than those without bedaquiline resistance at baseline. Complete data on MICs and genome sequencing would help to determine whether an association with treatment failure exists.

Parsimonious regimens such as those evaluated in the Nix-TB study may provide little support when drugs are rendered ineffective by resistance or incomplete adherence. One case (0.9%) of emerging resistance, which was reported in the study, is probably fewer than the number that would occur in the context of routine care in which intense monitoring rarely exists. We identified emerging bedaquiline resistance in 1.7% of the patients in our study (5 of 287 patients),² and in 3.3% (4 of 121 patients) in a study conducted in Germany.⁴ Resistance testing and enhanced adherence support must be available for all patients.

Camus Nimmo, M.B., B.S.

University College London
London, United Kingdom
c.nimmo.04@cantab.net

Kogieleum Naidoo, M.B., Ch.B., Ph.D.

CAPRISA MRC-HIV-TB Pathogenesis and Treatment
Research Unit
Durban, South Africa

Max O'Donnell, M.D., M.P.H.

Columbia University Medical Center
New York, NY

No potential conflict of interest relevant to this letter was reported.

1. Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. *N Engl J Med* 2020; 382:893-902.
2. Nimmo C, Millard J, Brien K, et al. Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. *Eur Respir J* 2020;55:1902383.
3. Colangeli R, Jedrey H, Kim S, et al. Bacterial factors that predict relapse after tuberculosis therapy. *N Engl J Med* 2018; 379:823-33.
4. Andres S, Merker M, Heyckendorf J, et al. Bedaquiline-resistant tuberculosis: dark clouds on the horizon. *Am J Respir Crit Care Med* 2020 February 13 (Epub ahead of print).

DOI: 10.1056/NEJMc2009939

TO THE EDITOR: We concur with Thwaites and Nahid¹ in their editorial that the landmark study by Conradie et al. offers hope for persons with drug-resistant tuberculosis. However, the fact that peripheral neuropathy, albeit mild and manageable, was reported in 81% of the patients shows that toxic effects associated with these high doses of linezolid are problematic.

Of the 77 patients who were receiving linezolid during their stay in our tuberculosis center between 2007 and 2019, a total of 20 (26%) had polyneuropathy. The linezolid dose was adjusted on the basis of the pharmacokinetic profile and drug susceptibility testing. The median final linezolid dose was 600 mg per day (interquartile range, 300 to 600). In some cases, the linezolid dose was reduced to 150 mg daily.²

With this clinical experience in mind, we are anxiously awaiting results from the successor of the Nix-TB study (ZeNix; ClinicalTrials.gov number, NCT03086486), in which patients are randomly assigned to receive one of several regimens of linezolid at lower doses. Perhaps therapeutic drug monitoring could be considered for patients who report toxic effects at these lower doses, despite challenges in assessing MICs in low- and middle-income countries. Although linezolid is a powerful treatment for drug-resistant tubercu-

Table 1. Minimum Inhibitory Concentrations (MICs) of *Mycobacterium tuberculosis* Isolates and Outcomes of the Three Patients.

Patient No.	Bedaquiline MIC	Pretomanid MIC <i>μg/ml</i>	Linezolid MIC	Week of Culture Conversion	Outcome
Patient 1	2	0.12	0.5	No culture conversion	Death at week 11 due to pneumonia and sepsis
Patient 2	4	0.12	0.5	2	Favorable at time of assessment of primary end point
Patient 3	2	0.25	0.5	8	Favorable at time of assessment of primary end point

losis, in the end, we need equally potent but less toxic derivatives, such as sutezolid.^{3,4}

Mathieu S. Bolhuis, Pharm.D., Ph.D.

Tjip S. van der Werf, M.D., Ph.D.

Onno W. Akkerman, M.D., Ph.D.

University of Groningen
Groningen, the Netherlands
m.s.bolhuis@umcg.nl

No potential conflict of interest relevant to this letter was reported.

1. Thwaites G, Nahid P. Triumph and tragedy of 21st century tuberculosis drug development. *N Engl J Med* 2020;382:959-60.

2. Bolhuis MS, van der Werf TS, Kerstjens HAM, de Lange WCM, Alffenaar J-WC, Akkerman OW. Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules. *Eur Respir J* 2019;54:1900580.

3. Alffenaar JWC, van der Laan T, Simons S, et al. Susceptibility of clinical *Mycobacterium tuberculosis* isolates to a potentially less toxic derivate of linezolid, PNU-100480. *Antimicrob Agents Chemother* 2011;55:1287-9.

4. Wallis RS, Dawson R, Friedrich SO, et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. *PLoS One* 2014; 9(4):e94462.

DOI: 10.1056/NEJMc2009939

THE AUTHORS REPLY: In response to Nimmo and colleagues: Table 1 shows the MICs of *Mycobacterium tuberculosis* isolates and the outcomes in the three patients who had baseline bedaquiline MICs above the critical concentration recommended by the World Health Organization (1 μ g per milliliter). All three patients had isolates that were susceptible to linezolid and low MICs for pretomanid.

Whole genome sequencing is in progress to determine mutations that may be associated with these elevated MICs. We agree that emergence of resistance is a concern with a new regimen. Surveillance programs are in place

worldwide to evaluate resistance to bedaquiline and linezolid and are planned to be initiated shortly for pretomanid. We encourage the availability of drug susceptibility testing, although whether this testing should be routine for all patients starting a new regimen will need to be determined by individual countries on the basis of resistance rates in their geographic regions. New treatment regimens that are combinations of drugs with low levels of resistance and that are simple, of short duration, and highly effective will enhance adherence.

We join Bolhuis and colleagues in eagerly awaiting the results of the ongoing ZeNix trial, which evaluates lower doses and shorter durations of linezolid treatment as part of the combination regimen of bedaquiline, pretomanid, and linezolid. The results of the trial will help to determine the need for new drugs in the oxazolidinone class that may have fewer adverse effects. Trials are needed to provide data on the value and successful outcomes of therapeutic drug monitoring for linezolid and to determine whether such monitoring is feasible in countries with high tuberculosis burdens.

Francesca Conradie, M.B., B.Ch.

University of Witwatersrand
Johannesburg, South Africa

Daniel Everitt, M.D.

TB Alliance
New York, NY

Angela M. Crook, M.Sc., Ph.D.

University College London
London, United Kingdom
angela.crook@ucl.ac.uk

Since publication of their article, the authors report no further potential conflict of interest.

DOI: 10.1056/NEJMc2009939